Shares of Nyxoah S.A. (NASDAQ:NYXH – Get Rating) have received an average recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $31.00.
NYXH has been the subject of a number of analyst reports. Oppenheimer assumed coverage on shares of Nyxoah in a research note on Wednesday, April 20th. They issued an “outperform” rating and a $30.00 target price for the company. Wolfe Research assumed coverage on shares of Nyxoah in a research report on Tuesday, April 5th. They issued a “market perform” rating and a $21.00 price target on the stock. Piper Sandler dropped their price target on shares of Nyxoah from $40.00 to $30.00 in a research report on Friday, March 25th. Finally, Zacks Investment Research lowered shares of Nyxoah from a “buy” rating to a “hold” rating in a research report on Friday, April 1st.
A number of large investors have recently made changes to their positions in NYXH. BlackRock Inc. bought a new stake in shares of Nyxoah in the 3rd quarter valued at about $19,612,000. Invesco Ltd. bought a new stake in Nyxoah during the 1st quarter worth approximately $8,177,000. RTW Investments LP bought a new stake in Nyxoah during the 3rd quarter worth approximately $10,087,000. Deerfield Management Company L.P. Series C bought a new stake in Nyxoah during the 3rd quarter worth approximately $8,797,000. Finally, Pura Vida Investments LLC bought a new stake in Nyxoah during the 3rd quarter worth approximately $6,542,000. 10.76% of the stock is owned by hedge funds and other institutional investors.
About Nyxoah (Get Rating)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
- Get a free copy of the StockNews.com research report on Nyxoah (NYXH)
- Two Retailers, One To Buy And One To Avoid
- Investors Can Get 5%-Plus Dividend Yields on These 3 Buys
- Indie Semiconductor Stock is Putting in a Bottom
- It’s Time to Buy into Planet Fitness Stock
- 3 Defensive Consumer Stocks Worth Shopping For
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.